Eli Lilly-backed Scribe Therapeutics climbs 67% after raising $128.7 million in an upsized IPO
Scribe Therapeutics, a developer of gene therapies for heart diseases, rose 67% after raising $128.7 million in its IPO.
Read the full story at mint - markets →